Rival stent makers join forces on clot-risk study
Just nine months ago, Boston Scientific Corp. and Johnson & Johnson were battling each other in a brutal takeover war for Guidant Corp. Now the two companies are joining forces to study a health issue that threatens a key business of both firms: the risk of blood clots associated with drug-coated stents. (Full article: 591 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
